Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 29, 2022 07:30 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates

– Company on Track for Mid-year Filing of Investigational New Drug (IND) Application for Lead Candidate MRT-2359 – – Progressed NEK7 and CDK2 Molecular Glue Degrader Programs into Lead Optimization –...
February 03, 2022 16:30 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences

BOSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, today announced that the company...
January 25, 2022 07:30 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics and Yeda, the commercial arm of the Weizmann Institute of Science, Announce License and Research Collaboration to Accelerate Discovery of Novel Covalent Molecular Glue Degraders

BOSTON and REHOVOT, Israel, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, announced a...
January 04, 2022 07:30 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, today announced that the company...
December 02, 2021 07:30 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Appoints Jullian G. Jones, Ph.D., J.D., MBA, as Chief Business Officer

BOSTON, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, today announced the promotion of...
November 22, 2021 07:30 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference

BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, today announced members of its...
November 10, 2021 07:30 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Announces First Development Candidate and Reports Third Quarter 2021 Financial Results and Business Updates

– Initiated Investigational New Drug (IND)-Enabling Activities for MRT-2359, a Molecular Glue Degrader Selectively Targeting GSPT1 – – Presented Preclinical Data at AACR-NCI-EORTC Highlighting...
October 20, 2021 07:30 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics to Present at 4th Annual Targeted Protein Degradation Summit

BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that Sharon...
October 07, 2021 09:00 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Presents Preclinical Data at AACR-NCI-EORTC Highlighting Potential of Molecular Glue Degraders for the Treatment of Myc-driven Cancer

BOSTON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue-based precision medicines, today announced preclinical...
September 30, 2021 16:30 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics to Present Late-breaking Preclinical Data on Targeting GSPT1 for Myc-driven Cancers at AACR-NCI-EORTC Virtual International Conference

BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that preclinical...